3 Stocks That May Be Trading At Discounts Of Up To 42.1%

In This Article:

In a week marked by mixed performances across major U.S. indices, with growth stocks significantly outpacing their value counterparts, investors are keenly observing the potential for undervalued opportunities amidst market volatility. As geopolitical tensions and economic data continue to shape the global landscape, identifying stocks that may be trading at a discount could offer strategic entry points for those looking to capitalize on market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

Hunan Jiudian Pharmaceutical (SZSE:300705)

CN¥26.16

CN¥52.08

49.8%

UMB Financial (NasdaqGS:UMBF)

US$122.36

US$244.39

49.9%

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211)

CN¥38.61

CN¥76.93

49.8%

S Foods (TSE:2292)

¥2742.00

¥5472.35

49.9%

Aguas Andinas (SNSE:AGUAS-A)

CLP288.85

CLP577.11

49.9%

Acerinox (BME:ACX)

€10.03

€20.04

49.9%

NCSOFT (KOSE:A036570)

₩204500.00

₩408990.47

50%

U.S. Physical Therapy (NYSE:USPH)

US$94.06

US$187.03

49.7%

Equifax (NYSE:EFX)

US$265.29

US$529.48

49.9%

Almacenes Éxito (BVC:EXITO)

COP2190.00

COP4369.08

49.9%

Click here to see the full list of 910 stocks from our Undervalued Stocks Based On Cash Flows screener.

Here's a peek at a few of the choices from the screener.

Genomma Lab Internacional. de

Overview: Genomma Lab Internacional, S.A.B. de C.V. operates in the pharmaceutical and personal care sectors primarily across Latin America, with a market capitalization of approximately MX$25.83 billion.

Operations: The company's revenue from the pharmaceutical and personal care products industry amounts to MX$17.47 billion.

Estimated Discount To Fair Value: 19.7%

Genomma Lab Internacional appears undervalued, trading at MX$27.33, approximately 19.7% below its estimated fair value of MX$34.02. Despite high debt levels, the company's earnings are forecast to grow 19.4% annually, outpacing the Mexican market's 12.3%. Recent Q3 results showed strong sales growth to MX$5.09 billion and net income increase to MX$660 million from the previous year, reinforcing its robust cash flow potential amidst positive industry compliance developments.

BMV:LAB B Discounted Cash Flow as at Dec 2024
BMV:LAB B Discounted Cash Flow as at Dec 2024

Henglin Home FurnishingsLtd

Overview: Henglin Home Furnishings Co., Ltd is involved in the research, development, production, and sale of office chairs, sofas, massage chairs, panel furniture, and system office products in China with a market cap of CN¥4.65 billion.